Elevance Health (NYSE:ELV) Stock Rating Upgraded by Zacks Research

Elevance Health (NYSE:ELV) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports. Zacks Research also issued estimates for Elevance Health’s Q1 2026 earnings at $11.38 EPS.

Several other research firms have also recently weighed in on ELV. Robert W. Baird lowered their target price on Elevance Health from $492.00 to $297.00 and set a “neutral” rating on the stock in a research note on Friday, July 25th. Barclays decreased their price target on shares of Elevance Health from $395.00 to $385.00 and set an “overweight” rating for the company in a report on Wednesday, October 22nd. Leerink Partnrs lowered shares of Elevance Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. TD Cowen lifted their target price on shares of Elevance Health from $330.00 to $380.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, The Goldman Sachs Group started coverage on shares of Elevance Health in a research note on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 price target on the stock. Twelve analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $397.33.

Elevance Health Trading Up 1.0%

NYSE ELV traded up $3.07 on Thursday, hitting $317.51. 1,151,441 shares of the stock were exchanged, compared to its average volume of 1,950,748. The company’s 50-day moving average price is $329.41 and its two-hundred day moving average price is $345.36. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.56 and a quick ratio of 1.56. Elevance Health has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a market capitalization of $70.56 billion, a price-to-earnings ratio of 12.98, a P/E/G ratio of 1.23 and a beta of 0.60.

Elevance Health (NYSE:ELV) last issued its earnings results on Tuesday, October 21st. The company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.03 by $1.00. The business had revenue of $50.09 billion during the quarter, compared to analysts’ expectations of $49.26 billion. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.Elevance Health’s revenue was up 12.0% compared to the same quarter last year. During the same quarter last year, the firm posted $8.37 earnings per share. Research analysts predict that Elevance Health will post 33.96 EPS for the current year.

Insider Buying and Selling

In related news, Director Susan D. Devore bought 1,200 shares of the business’s stock in a transaction on Tuesday, August 19th. The shares were bought at an average cost of $312.15 per share, for a total transaction of $374,580.00. Following the completion of the acquisition, the director directly owned 3,502 shares in the company, valued at approximately $1,093,149.30. This represents a 52.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.29% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. GLOBALT Investments LLC GA boosted its holdings in Elevance Health by 0.4% in the 1st quarter. GLOBALT Investments LLC GA now owns 6,306 shares of the company’s stock valued at $2,743,000 after purchasing an additional 24 shares during the period. Hemington Wealth Management lifted its stake in shares of Elevance Health by 13.3% in the first quarter. Hemington Wealth Management now owns 230 shares of the company’s stock valued at $100,000 after buying an additional 27 shares during the period. Aspen Investment Management Inc grew its position in Elevance Health by 2.6% during the first quarter. Aspen Investment Management Inc now owns 1,048 shares of the company’s stock worth $456,000 after buying an additional 27 shares in the last quarter. Prudent Man Advisors LLC increased its stake in Elevance Health by 2.3% during the first quarter. Prudent Man Advisors LLC now owns 1,257 shares of the company’s stock valued at $547,000 after acquiring an additional 28 shares during the period. Finally, Nilsine Partners LLC raised its holdings in Elevance Health by 1.5% in the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after acquiring an additional 29 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.